April 16, 2024

Genomate Health Raises $2.25M for AI-Based Model to Predict Targeted Cancer Therapy Response

April 16, 2024

…NEW YORK – Genomate Health on Tuesday said it raised $2.25 million in funding to further develop and pursue US Food and Drug Administration clearance for an artificial intelligence-driven computational model that predicts therapeutic response to molecularly targeted cancer drugs...

Other Media Coverage

See all

Genomate Health Welcomes Digosys (Thabis) as Vietnam Exclusive Distributor

November 4, 2024

Read Article

DiMe and Moffitt Cancer Center to Co-Host Cancer Moonshot's New CancerX Public-Private Partnership

March 23, 2023

Read Article

Computational Reasoning for the N-of-1 Use of Molecularly Targeted Cancer Therapies

May 15, 2024

Read Article

Other Resources

The Genomate® Report can be used and clinically interpreted only by physicians or other qualified healthcare professionals. Genomate® is a clinical decision support software and is not intended to diagnose, treat, cure, prevent, or mitigate any condition. None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Learn more.